Already the largest biopharma company in India, generics powerhouse Sun Pharma has doubled in size with its acquisition (PDF) ...

MUMBAI, India & JERSEY CITY, N.J. Sun Pharmaceutical Industries Limited (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715) (together with its subsidiaries and/or associated companies, ...

To fuel its global ambitions, Sun Pharmaceutical Industries will acquire New Jersey-based Organon & Co in an all-cash deal ...

Indian generic medicines giant Sun Pharmaceutical Industries is buying the women’s health company Organon in a deal worth $11 ...

Sun Pharma has offered to pay $14 a share in an all-cash deal, putting the Indian drugmaker on track to become one of the top ...

Sun Pharma will acquire Organon for $11.75 billion. Astellas projects Xtandi sales to decline in fiscal year 2026. | Sun ...

On April 26, 2026, Sun Pharmaceutical Industries confirmed that it would acquire Organon & Co. (NYSE:OGN), a U.S. drugmaker, ...

Shares of womens healthcare company Organon Co (NYSE: OGN) climbed sharply in after-hours trading on Thursday following ...

Post-Organon deal, ICICI Direct downgraded Sun Pharma to Hold, IIFL adjusted to Add, Investec maintained a Sell rating, while ...

Organon’s portfolio includes more than 70 products across women’s health and general medicines, including biosimilars.

Sun Pharma sees its Organon acquisition as a platform to expand globally, boost in-licensing, and improve long-term ...

April 26 () - Sun Pharmaceutical Industries said on Sunday it will ‌buy Organon & Co in an ‌all‑cash deal, valuing the U.75 ...